🇺🇸 FDA
Patent

US 11976122

Anti-IL13Rα2 antibodies

granted A61KA61K47/6801A61P

Quick answer

US patent 11976122 (Anti-IL13Rα2 antibodies) held by ADC THERAPEUTICS SA expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ADC THERAPEUTICS SA
Grant date
Tue May 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61K, A61K47/6801, A61P, A61P35/00